COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
 
Home   
Share  
  OutcomesOutcomes
  Global AdoptionAdoption
  Submit FeedbackFeedback
00.250.50.7511.251.51.752+Chen (RCT)74%0.26 [0.09-0.75]hosp.5/3099/143Improvement, RR [CI]TreatmentControlGottlieb (RCT)71%0.29 [0.09-0.96]hosp./ER4/1017/52Lilly (DB RCT)92%0.08 [0.00-1.43]death0/5114/258Webb80%0.20 [0.03-1.46]death1/47957/5,536Tau​2 = 0.00; I​2 = 0.0%Early treatment76%0.24 [0.12-0.50]10/1,40077/5,98976% improvementACTIV-3/T.. (RCT)-100%2.00 [0.69-5.83]death9/1635/151Improvement, RR [CI]TreatmentControlBariola67%0.33 [0.10-1.01]death4/23412/234Tau​2 = 1.30; I​2 = 80.7%Late treatment18%0.82 [0.14-4.77]13/39717/38518% improvementLilly (RCT)57%0.43 [0.27-0.69]symp. case483482Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP57%0.43 [0.27-0.69]0/4830/48257% improvementAll studies59%0.41 [0.23-0.74]23/2,28094/6,85659% improvement7 bamlanivimab COVID-19 studiesc19ly.com 7/30/21Tau​2 = 0.26; I​2 = 46.8%; Z = 2.98 (p = 0.0014)Effect extraction pre-specifiedLower RiskIncreased Risk
LY-CoV555 and LY-CoV016 are two SARS-CoV-2 neutralizing antibodies which bind complementary regions of the SARS-CoV-2 spike protein. Studies are investigating their use in monotherapy and in combination. Submit updates/corrections below.
6/23
Early Webb et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab331 (Peer Reviewed) death, ↓79.7%, p=0.09 Real-World Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients with Early COVID-19
Details   Retrospective 479 patients treated with bamlanivimab showing lower mortality, hospital admission, and emergency department visits with treatment. Authors falsely state that "no other COVID-19 therapies for ambulatory patients have pr..
3/30
Late Bariola et al., medRxiv, doi:10.1101/2021.03.25.21254322 (Preprint) death, ↓66.8%, p=0.05 Impact of monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with SARS-CoV-2 infection
Details   Retrospective 234 patients receiving bamlanivimab and 234 matched controls, showing lower hospitalization and mortality with treatment. Greater benefit was seen with administration within 4 days of their positive COVID-19 test.
3/10
Early Lilly, Press Release (Preprint) death, ↓92.3%, p=0.01 Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19
Details   Results from the BLAZE-1 study of combined bamlanivimab/etesevimab, showing significantly lower mortality and combined mortality/hospitalization with treatment.
1/21
PrEP Lilly, Press Release (Preprint) symp. case, ↓57.0%, p=0.0002 Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents
Details   Press release on the BLAZE-2 trial at nursing homes showing significantly lower symptomatic COVID-19 with treatment.
1/21
Early Gottlieb et al., JAMA, doi:10.1001/jama.2021.0202 (Peer Reviewed) hosp./ER, ↓70.6%, p=0.05 Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
Details   RCT for LY-CoV555 monotherapy and LY-CoV555/LY-CoV016 combination therapy with 592 patients showing lower hospitalization/ER visits with treatment. For viral load at day 11, a statistically significant reduction was found with combinatio..
12/22
Late ACTIV-3/TICO LY-CoV555 study group, NEJM, doi:0.1056/NEJMoa2033130 (Peer Reviewed) death, ↑100%, p=0.22 A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
Details   Late stage RCT of LY-CoV555 added to remdesivir, showing non-statistically significant higher mortality with the addition of LY-CoV555.
10/28
Early Chen et al., NEJM, doi:10.1056/NEJMoa2029849 (Peer Reviewed) hosp., ↓74.3%, p=0.02 SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Details   Interim analysis of the BLAZE-1 phase 2 trial of outpatients showing lower hospitalization or ER visits (1.6% versus 6.3%), and improvements in symptoms and viral load compared to placebo. NCT04427501
10/26
News Lilly, Press Release (News) news Lilly Statement Regarding NIH’s ACTIV-3 Clinical Trial
Details   ACTIV-3 intermin analysis shows LY-CoV555 is unlikely to help hospitalized patients. ACTIV-2, BLAZE-1 and BLAZE-2 trials remain ongoing.
10/7
Early Lilly, Press Release (Preprint) hosp., ↓84.5%, p=0.05 SARS-CoV-2 neutralizing antibody program update
Details   Interim results from the BLAZE-1 outpatient RCT showing improvements in viral load, symptoms and hospitalization. Combination therapy significantly reduced viral load at day 11 (p=0.011). A greater effect is seen at day 7 (p<0.001). The ..
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit